Why the study?
Does eprosartan reduce pulse pressure in patients with mild-to-moderate essential hypertension?
Does eprosartan reduce pulse pressure in patients with mild-to-moderate essential hypertension?
Eprosartan 600 mg/day is effective and well-tolerated for reducing pulse pressure and overall blood pressure in primary care patients with mild-to-moderate hypertension.
Observational data support eprosartan in mild-to-moderate hypertension; leaves open comparative outcomes versus other agents in RCTs.
A multicentre, prospective, non-comparative open-label study was conducted to assess the effect of eprosartan, 600 mg/day, on pulse pressure (PP) in patients with hypertension (stage I or II, Joint National Committee, sixth report) treated in the primary care setting, as well as safety and compliance. The duration of treatment was 16 weeks. Eprosartan decreased PP (-13 mmHg), systolic blood pressure (SBP) (-26 mmHg), diastolic blood pressure (DBP) (-13 mmHg) and mean arterial pressure (MAP) (-17.4 mmHg) significantly (p < 0.0001). The PP/MAP ratio changed significantly from 62 to 59%, so that the reduction of PP was 3% higher than the overall decrease in MAP. Twenty adverse events, mostly gastrointestinal complaints, were recorded in 12 patients (1.9%). Compliance with treatment at the end of the study was 94%. Eprosartan was a well-tolerated and an effective drug in reducing PP, SBP and DBP below the recommended levels in patients with mild-to-moderate essential hypertension, allowing a high therapeutic compliance.
No takes yet. Share an insight, caveat, or question.
Robles et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: